Core Viewpoint - Lupin has reached a Settlement and License Agreement with Astellas Pharma regarding a patent infringement dispute over the product 'Mirabegron', allowing Lupin to continue selling its version of the drug while resolving ongoing litigation [1][2]. Group 1: Financial Terms of the Settlement - Lupin will pay Astellas a total of $90 million, which includes a Prepaid Option Payment of $75 million and a Prepaid Per Unit License Fee for each unit of Lupin's product sold until September 2027 [1]. Group 2: Product Information - The product in question, Mirabegron, is used to treat overactive bladder symptoms, including urge urinary incontinence, urgency, and urinary frequency, and is marketed by Astellas under the Myrbetriq trademark [2]. Group 3: Ongoing Litigation - Astellas has indicated that litigation involving Myrbetriq with other companies is still ongoing and is assessing the potential financial impact of these developments for the fiscal year ending March 31, 2026 [3].